Standard Operating Procedure for Tracking Open Variations and Supplements
| Department | Regulatory Affairs |
| SOP No. | RA/2026/674 |
| Supersedes | NA |
| Page No. | 1 of X |
| Issue Date | 11/04/2026 |
| Effective Date | 11/04/2026 |
| Review Date | 11/04/2028 |
Purpose
This Standard Operating Procedure (SOP) establishes a systematic approach for tracking all open variations and supplements pertaining to post-approval changes in regulatory submissions. It ensures timely monitoring, documentation, and management of all updates throughout their lifecycle, thereby supporting compliance with regulatory requirements and maintaining the integrity of approved dossiers. This SOP facilitates control over submission statuses, timelines, and coordination across functional areas involved in regulatory affairs.
Scope
This SOP applies to the Regulatory Affairs department and covers all types of post-approval changes including variations, supplements, amendments, and other lifecycle maintenance submissions related to any pharmaceutical product, dosage form, or device managed by the organization. It includes tracking from initiation through regulatory review to final closure. Activities outside regulatory submissions management such as change implementation or quality control testing are excluded unless directly impacting variation tracking.
Responsibilities
- Regulatory Affairs Executives: Initiate tracking, maintain variation records, update status, and communicate with stakeholders.
- Regulatory Affairs Manager: Review and approve tracking data, ensure correct prioritization and workflow compliance.
- Quality Assurance: Verify data completeness during review and ensure adherence to regulatory standards.
- Cross-functional Team Members: Provide timely inputs and documentation required for submission progress updates.
- Document Control: Maintain version control of related tracking documents and records.
Accountability
The Regulatory Affairs Head holds overall accountability for the implementation, adherence, periodic review, and effectiveness of this SOP. They are responsible for escalation of deviations, ensuring regulatory compliance, and driving continuous improvement in the tracking process.
Procedure
The following stepwise procedure outlines the comprehensive process for tracking open variations and supplements:
1. Preparation and Prerequisites: Prior to initiating tracking, ensure that all relevant submission details, including variation types, regulatory agency requirements, submission dates, and applicable regions, are documented correctly in the tracking system or log.
2. Initiation of Tracking Record: Upon identification or receipt of a post-approval change, create an entry in the Variation Tracking Log capturing essential data such as submission number, product name, description of change, submission date, expected timelines, and responsible persons.
3. Status Updates and Monitoring: Regularly update the tracking log with progress milestones, including submission acceptance, query receipt, response submission, and final approval or rejection. Monitor due dates rigorously to ensure timely follow-ups.
4. Communication and Coordination: Facilitate communication between regulatory agencies, internal functions (e.g., Quality, Manufacturing, Documentation), and external partners if applicable. Circulate status reports at pre-defined intervals or upon request.
5. In-Process Controls: Verify completeness and accuracy of documents submitted with each variation. Confirm alignment with regulatory guidelines and internal procedural requirements prior to submission and upon receipt of queries.
6. Deviation and Issue Handling: Any delays, discrepancies, or adverse agency responses must be documented as deviations and reported promptly to the Regulatory Affairs Manager for corrective action and escalation.
7. Approval and Closure: Once a variation or supplement is finalized and approved by the regulatory authority, update the tracking system to indicate closure, archive relevant documentation, and notify all stakeholders. Ensure proper document reconciliation in Regulatory Master Files.
8. Documentation and Record Retention: Maintain all tracking logs, correspondence, approval letters, and related documentation as per company record retention policy and regulatory expectations to support audits and inspections.
9. Review and Continuous Improvement: Conduct periodic reviews of the tracking process effectiveness, update SOP as necessary, and provide training or process enhancements to improve compliance and efficiency.
This procedure must be performed adhering strictly to applicable GMP, GCP, and regulatory frameworks relevant to the product and geography. Use of electronic tracking tools should be validated and access controlled.
Abbreviations
- SOP – Standard Operating Procedure
- RA – Regulatory Affairs
- GMP – Good Manufacturing Practice
- GCP – Good Clinical Practice
- API – Active Pharmaceutical Ingredient
- QA – Quality Assurance
- CF – Cross-functional
Documents
The following documents are essential for the effective tracking of open variations and supplements:
- Variation Tracking Log (Annexure-1)
- Submission Status Report Template (Annexure-2)
- Variation Closure Form (Annexure-3)
References
- ICH Q9 Quality Risk Management
- FDA Guidance for Industry: Changes to an Approved NDA or ANDA
- EU Guidelines on Variations to Marketing Authorisations
- Company Quality Manual and Document Control Policies
- Pharmaceutical Regulatory Frameworks Applicable to Marketed Products
Version
1.0
Approval
| Prepared By | |
| Checked By | |
| Approved By |
Annexures
Annexure-1: Variation Tracking Log
Purpose: To maintain a comprehensive and up-to-date record of all open variations and supplements under regulatory review.
| Entry Date | Variation ID | Product Name | Change Description | Submission Date | Responsible Person | Current Status | Expected Completion |
|---|---|---|---|---|---|---|---|
| 02/03/2026 | VAR-2026-015 | Tablet XYZ 50mg | Labeling Update | 05/03/2026 | Regulatory Executive | Under Review | 20/05/2026 |
| 10/03/2026 | VAR-2026-020 | Injection ABC 10ml | Manufacturing Site Change | 12/03/2026 | Regulatory Executive | Accepted | 30/06/2026 |
Annexure-2: Submission Status Report Template
Purpose: To provide periodic summarized updates on the status of all open variations and supplements.
| Report Date | Variation ID | Product | Status | Next Action Required | Comments |
|---|---|---|---|---|---|
| 15/04/2026 | VAR-2026-015 | Tablet XYZ 50mg | Under Review | Prepare Reply to Questions | Received initial queries on 10/04/2026 |
| 15/04/2026 | VAR-2026-020 | Injection ABC 10ml | Accepted | File Closure Pending | Awaiting final approval letter |
Annexure-3: Variation Closure Form
Purpose: To formally document the closure of a variation once the regulatory authority has granted approval and all related activities are completed.
| Variation ID | VAR-2026-015 |
| Product Name | Tablet XYZ 50mg |
| Closure Date | 21/04/2026 |
| Regulatory Approval Reference | Letter Ref #RA-2026-789 |
| Summary of Change | Labeling Update approved and implemented |
| Comments | All documentation archived per record retention policy |
| Prepared By | |
| Checked By | |
| Approved By |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
| 11/04/2026 | 1.0 | Initial issue | New SOP creation |